PHAF1/MYTHO is a novel autophagy regulator that controls muscle integrity

• Published in: Autophagy Vol. 20; no. 4; pp. 965 - 967
• Main Authors: Franco-Romero, Anais, Leduc-Gaudet, Jean Philippe, Hussain, Sabah NA, Gouspillou, Gilles, Sandri, Marco
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 02.04.2024
• Subjects: Animals; Autophagic Punctum; autophagy; Autophagy - physiology; FoxO; Humans; Mechanistic Target of Rapamycin Complex 1 - metabolism; Models, Biological; mTOR; muscle atrophy; Muscle, Skeletal - metabolism; Muscle, Skeletal - pathology; Muscular Atrophy - metabolism; Muscular Atrophy - pathology; Myopathy; myotonic dystrophy type 1; mTOR; FoxO; autophagy; muscle atrophy; myotonic dystrophy type 1; Myopathy
• ISSN: 1554-8627; 1554-8635; 1554-8635
• DOI: 10.1080/15548627.2023.2224206

Skeletal muscles play key roles in movement, posture, thermogenesis, and whole-body metabolism. Autophagy plays essential roles in the regulation of muscle mass, function and integrity. However, the molecular machinery that regulates autophagy is still incompletely understood. In our recent study, we identified and characterized a novel Forkhead Box O (FoxO)-dependent gene, PHAF1/MYTHO (phagophore assembly factor 1/macro-autophagy and youth optimizer), as a novel autophagy regulator that controls muscle integrity. MYTHO/PHAF1 is upregulated in multiple conditions leading to muscle atrophy, and downregulation of its expression spares muscle atrophy triggered by fasting, denervation, cachexia and sepsis. Overexpression of PHAF1/MYTHO is sufficient to induce muscle atrophy. Prolonged downregulation of PHAF1/MYTHO causes a severe myopathic phenotype, which is characterized by impaired autophagy, muscle weakness, myofiber degeneration, mammalian target of rapamycin complex 1 (mTORC1) hyperactivation and extensive ultrastructural defects, such as accumulation of proteinaceous and membranous structures and tubular aggregates. This myopathic phenotype is attenuated upon administration of the mTORC1 inhibitor rapamycin. These findings position PHAF1/MYTHO as a novel regulator of skeletal muscle autophagy and tissue integrity.